Drug intelligence / Profile preview

BSC1302

Development stage: Preclinical
Lead developer: BiSiChem
Modality: Small Molecules
Administration: Ophthalmic

Overview

BSC1302 is a small molecule inhibitor of Receptor-Interacting Protein Kinase 1 (RIPK1) currently in preclinical development by BiSiChem. It is specifically formulated as an eye drop for the treatment of retinal diseases. RIPK1 is a critical signaling protein that regulates programmed cell death (necroptosis) and inflammatory signaling pathways. In the context of retinal diseases, excessive RIPK1 activity is associated with photoreceptor cell loss and neuroinflammation. BSC1302 aims to preserve retinal function by blocking these pathological processes, potentially offering a new therapeutic approach for various degenerative retinal conditions.

Targets

RIPK1 (Receptor-interacting serine/threonine-protein kinase 1)

Beyond the preview

Go deeper on BSC1302.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BSC1302.

Explore the full profile